Sphera Funds Management Ltd. Chinook Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $753,550 - $938,000	-35,000 Reduced 27.52%	92,200 $2.13 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $7.59 Million - $11.1 Million	-407,158 Reduced 76.2%	127,200 $3.33 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $1.92 Million - $2.56 Million	-109,373 Reduced 16.99%	534,358 $10.5 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $1.89 Million - $2.82 Million	150,054 Added 30.4%	643,731 $11.3 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $4.59 Million - $6.38 Million	382,024 Added 342.15%	493,677 $8.08 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $1.19 Million - $1.88 Million	111,653 New	111,653 $1.82 Million
Q2 2021 Aug 17, 2021	SELL	$13.6 - $18.98 $1.38 Million - $1.93 Million	-101,666 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $1.42 Million - $1.91 Million	-100,000 Reduced 49.59%	101,666 $1.58 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $2.4 Million - $4.22 Million	201,666 New	201,666 $3.2 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.